131 related articles for article (PubMed ID: 17454589)
21. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.
Perry CM; Jarvis B
Drugs; 2001; 61(15):2263-88. PubMed ID: 11772139
[TBL] [Abstract][Full Text] [Related]
22. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
Rasenack J; Zeuzem S; Feinman SV; Heathcote EJ; Manns M; Yoshida EM; Swain MG; Gane E; Diago M; Revicki DA; Lin A; Wintfeld N; Green J
Pharmacoeconomics; 2003; 21(5):341-9. PubMed ID: 12627987
[TBL] [Abstract][Full Text] [Related]
23. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
24. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
26. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
Sacchi S; Kantarjian HM; Smith TL; O'Brien S; Pierce S; Kornblau S; Beran M; Keating MJ; Talpaz M
J Clin Oncol; 1998 Mar; 16(3):882-9. PubMed ID: 9508169
[TBL] [Abstract][Full Text] [Related]
27. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L
J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006
[TBL] [Abstract][Full Text] [Related]
28. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
[TBL] [Abstract][Full Text] [Related]
29. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
Talpaz M; Kantarjian H; Kurzrock R; Trujillo JM; Gutterman JU
Ann Intern Med; 1991 Apr; 114(7):532-8. PubMed ID: 2001086
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of the factors for predicting the outcomes of interferon-α and entecavir treatments for chronic hepatitis B with positive HBeAg].
Xie Z; Zhou F; Zhou Y
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):878-81. PubMed ID: 23803202
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
[No Abstract] [Full Text] [Related]
32. Interferon alfa-2a (Roferon-A) monotherapy in chronic myelogenous leukemia: a pilot study in Nigerian patients in early chronic phase.
Okanny CC; Durosimi MA; Chukwuani CM; Njoku OS; Akinola NO; Herrada SC; Ogbe OP; Onwukeme KE; Faluyi JO; Akanmu AS; Akinsete I
West Afr J Med; 2000; 19(4):286-92. PubMed ID: 11391843
[TBL] [Abstract][Full Text] [Related]
33. [Pegylated interferon alpha 2a in treating chronic hepatitis B patients].
Tian YL; Zhao W; Shen L; Liu W; Chang JB; Fang ZX; Yin WW; Wang L; Sun XB; Yang YJ
Zhonghua Gan Zang Bing Za Zhi; 2006 Nov; 14(11):806-10. PubMed ID: 17125604
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
[TBL] [Abstract][Full Text] [Related]
35. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C.
Sadeghi F; Bokharaei-Salim F; Salehi-Vaziri M; Monavari SH; Alavian SM; Salimi S; Vahabpour R; Keyvani H
J Med Virol; 2014 Sep; 86(9):1499-506. PubMed ID: 24889558
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.
Pockros PJ; Carithers R; Desmond P; Dhumeaux D; Fried MW; Marcellin P; Shiffman ML; Minuk G; Reddy KR; Reindollar RW; Lin A; Brunda MJ;
Am J Gastroenterol; 2004 Jul; 99(7):1298-305. PubMed ID: 15233669
[TBL] [Abstract][Full Text] [Related]
37. Peginterferon alfa-2a in patients with chronic hepatitis C.
Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
[TBL] [Abstract][Full Text] [Related]
38. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
[TBL] [Abstract][Full Text] [Related]
39. [Observation on effect of peg interferon lphaa-2a treating lamivudine resistant chronic hepatitis B].
Bai HL; Luo HT; Ye YN; Long H; Zhong RX
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Jun; 24(3):230-1. PubMed ID: 21186536
[TBL] [Abstract][Full Text] [Related]
40. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
